Celgene/Bristol's Revlimid Patent Risk Incrementally Lower After PTAB Denies Alvogen IPR

Bristol-Myers Squibb pitches Celgene's pipeline as its most valuable asset, but investors remain fixated on the coming Revlimid patent cliff. A recent PTAB decision to deny an inter partes review incrementally decreased that risk.